Iovance Biotherapeutics, Inc.
IOVA
$2.21
$0.083.51%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 12.52% | 21.55% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.52% | 21.55% | |||
| Cost of Revenue | -32.10% | 13.92% | |||
| Gross Profit | 781.33% | 888.49% | |||
| SG&A Expenses | -8.34% | -14.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.51% | 1.87% | |||
| Operating Income | 21.11% | 6.14% | |||
| Income Before Tax | 14.60% | 7.06% | |||
| Income Tax Expenses | -220.98% | 208.16% | |||
| Earnings from Continuing Operations | 18.27% | 3.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.27% | 3.88% | |||
| EBIT | 21.11% | 6.14% | |||
| EBITDA | 22.64% | 7.35% | |||
| EPS Basic | 24.90% | 7.23% | |||
| Normalized Basic EPS | 25.82% | 11.91% | |||
| EPS Diluted | 24.90% | 7.23% | |||
| Normalized Diluted EPS | 25.82% | 11.91% | |||
| Average Basic Shares Outstanding | 8.83% | 3.61% | |||
| Average Diluted Shares Outstanding | 8.83% | 3.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||